Five Forces Shaping Dental Tech in 2026: Revere Partners’ Mid-Year View
Dental care demand is resilient—Americans spent $189 billion in 2024, tied for the highest annual total this century—but delivery margins are the tightest in years, a dynamic the ADA Health Policy Institute calls a “fiscal squeeze.” Revere Partners identifies five forces reshaping oral health in 2026: efficiency software as the only fully controlled margin lever amid labor shortages; a widening case-acceptance gap, with nearly half of practices converting just 40–70% of treatment plans; FDA-cleared clinical AI becoming table stakes as dental tech funding hit roughly $2.1 billion in 2025; private-equity consolidation moving upmarket into specialties trading at 8–15x EBITDA; and new state M&A scrutiny like California’s AB 1415 turning compliance into a growth vertical.
For multi-site operators and their PE sponsors, the mid-year signal is clear: organic margin expansion now hinges on efficiency software and case-acceptance tooling, while a wave of 2020–2021 vintage platforms approaching exit sets up an active recapitalization market—amid rising state compliance risk that can make or break a deal.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
What EBITDA multiples are dental specialty practices commanding in 2026?
Specialty dental practices—oral surgery, orthodontics, endodontics, and pediatrics—are trading at roughly 8–15x EBITDA, versus 5–7x for general single-location practices. As general dentistry consolidates, private-equity capital is moving upmarket into these higher-margin, higher-barrier specialties, with premium multi-site platforms commanding even higher multiples.
How much venture capital is flowing into dental technology?
Dental tech venture funding reached roughly $2.1 billion in 2025, up about 18% from 2024, with capital concentrated in solutions that offset labor shortages. FDA-cleared clinical AI vendors such as Pearl, Overjet, and VideaHealth lead the field, and 2026 rounds already include VideaHealth’s $40M Series B and Archy’s $20M Series B.
How is new state regulation affecting dental M&A?
California’s AB 1415 and SB 351 took effect January 1, 2026, requiring pre-closing notice from PE groups, hedge funds, and MSOs and codifying corporate-practice restrictions—with enforcement already underway. Five states passed material-change notification laws, making regulatory compliance a de facto growth vertical and a diligence gate for dental deals.